



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/205791/2022

European Medicines Agency decision P/0178/2022

of 13 May 2022

on the granting of a product specific waiver for dupilumab (Dupixent), (EMEA-001501-PIP11-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0178/2022

of 13 May 2022

on the granting of a product specific waiver for dupilumab (Dupixent), (EMA-001501-PIP11-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Sanofi-Aventis Group on 20 December 2021 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 March 2022 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A waiver for dupilumab (Dupixent), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Sanofi-Aventis Group, 54 rue la Boétie, 75008 – Paris, France.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/23706/2022
Amsterdam, 25 March 2022

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001501-PIP11-21

Scope of the application

Active substance(s):

Dupilumab

Invented name:

Dupixent

Condition(s):

Treatment of chronic puritus of unknown origin

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Sanofi-Aventis Group

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Sanofi-Aventis Group submitted to the European Medicines Agency on 20 December 2021 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 31 January 2022.



Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of chronic pruritus of unknown origin

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of atopic dermatitis

Authorised indication(s):

- Dupixent is indicated for the treatment
 - of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
 - of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

2. Treatment of asthma

- Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment.

3. Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

- Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use